AstraZeneca is implementing N-Side’s recently launched Suite for Clinical Trials to provide ‘a single source of truth’ for safely supplying trials, as more stakeholders are generating more data.
AstraZeneca enters a $270m deal with Cheplapharm to divest seven drugs, in order to reduce its portfolio of ‘mature’ medicines and reinvest in other therapeutic areas.
Rho experts speak to the challenges facing drug development, meeting unmet needs, quality by design, and advances in technology, among other topics, during a sit-down at the CRO’s headquarters.